Ignite Creation Date:
2024-05-06 @ 7:32 AM
Last Modification Date:
2024-10-26 @ 11:49 AM
Study NCT ID:
NCT02555761
Status:
COMPLETED
Last Update Posted:
2019-07-05
First Post:
2015-09-18
Brief Title:
Safety and Efficacy of Lastacaft for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Sponsor:
Allergan
Organization:
Allergan
Study Overview
Official Title:
Evaluation of the Safety and Effectiveness of Lastacaft Ophthalmic Solution 025 Alcaftadine for the Prevention of Itching Associated With Allergic Conjunctivitis A Postmarketing Surveillance Study in Korea
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft Opthalmic Solution 025 Alcaftadine for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None